



PU4760USW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gudmundsson et al.

Serial No.: 10/505,386

Group Art Unit: 1614

File Date: August 20, 2004

Examiner:

For: Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions  
Containing Them

Director of the U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: References 2-23  
☐ Copies of the references were submitted in parent application \_\_\_\_\_ (37 CFR 1.98(d))  
☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan

Registration No. 38,181

Date: 3/1/05  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-8222  
Facsimile: (919) 483-7988

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)**Applicant(s): **Gudmundsson et al.**

Docket No.

**PU4760USW**

Serial No.

**10/505,386**

Filing Date

**August 20, 2004**

Examiner

Group Art Unit

**1614**Invention: **Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them**MAR 07 2005I hereby certify that this **Supplemental IDS w/accompanying papers**

(Identify type of correspondence)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 1, 2005

(Date)

**Valerie L. Phillips**

(Typed or Printed Name of Person Mailing Correspondence)

  
(Signature of Person Mailing Correspondence)


**FORM TO-1449**  
**INFORMATION DISCLOSURE STATEMENT**

ATTORNEY DOCKET NO.

PU4760USW

SERIAL NO.

10/505,386

APPLICANT: Gudmundsson et al.

FILING DATE:

8/20/04

GROUP

1614

**U.S. PATENT DOCUMENTS**

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	6,313,124	Nov. 6, 2001	He et al.			

Continue on page \_\_\_\_\_

**FOREIGN PATENT DOCUMENTS**

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes   No
	2	JP20000038350	Feb. 8, 2000	JAPAN			Abstract only
	3	WO 96/34866	Nov. 7, 1996	WIPO			
	4	WO 98/03510	Jan. 29, 1998	WIPO			
	5	WO 98/08847	Mar. 5, 1998	WIPO			
	6	WO 00/59907	Oct. 12, 2000	WIPO			
	7	WO 01/23387	Apr. 5, 2001	WIPO			
	8	WO 01/23388	Apr. 5, 2001	WIPO			
	9	WO 02/04424	Jan. 17, 2002	WIPO			
	10	WO 02/078700	Jan. 31, 2002	WIPO			
	11	WO 02/48147	June 20, 2002	WIPO			
	12	WO 02/48148	June 20, 2002	WIPO			
	13	WO 02/066481	Aug. 29, 2002	WIPO			
	14	WO 02/072581	Sept. 19, 2002	WIPO			
	15	WO 02/078701	Oct. 10, 2002	WIPO			
	16	WO 02/083672	Oct. 24, 2002	WIPO			
	17	WO 02/088124	June 7, 2002	WIPO			
	18	WO 03/000689	Jan. 3, 2003	WIPO			
	19	WO 03/022845	Mar. 20, 2003	WIPO			
	20	WO 03/031446	Apr. 17, 2003	WIPO			
	21	WO 03/050120	June 19, 2003	WIPO			
	22	WO 03/095455	Nov. 20, 2003	WIPO			
	23	WO 04/033454	Apr. 22, 2004	WIPO			

Continue on page \_\_\_\_\_

**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**


Continue on page \_\_\_\_\_

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.